TriangleFOR PATIENTS · SOURCE READING
Treatment of Acute Myeloid Leukemia in Remission
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: May 16, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Treatment of acute myeloid leukemia (AML) during the remission phase depends on the subtype of AML and may include:
combination chemotherapy that includes cytarabine
Source links and citations
maintenance therapy with midostaurin, for people whose AML has a mutation in the FLT3 gene
Source links and citations
maintenance therapy with chemotherapy
Source links and citations
high-dose chemotherapy and stem cell transplant using the patient's stem cells
Source links and citations
high-dose chemotherapy, with or without radiation therapy, or reduced-intensity therapy, followed by a stem cell transplant using donor stem cells
Source links and citations
Learn more about these treatments in Treatment Option Overview.
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice